Potential of ADCs in treating melanoma скачать в хорошем качестве

Potential of ADCs in treating melanoma

Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, reflects on the potential of antibody-drug conjugates (ADCs) in treating melanoma, highlighting the importance of the payload in determining the therapy's effectiveness. Prof. Long notes that while ADCs show great promise across the oncology field, the durability of the response is a key concern, particularly when using chemotherapy payloads. This interview took place at the 11th World Congress of Melanoma and 21st EADO Congress in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.